Company news

Ardelyx, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

February 21, 2022

Ardelyx Launching IBSRELA® Second Quarter of 2022

November 29, 2021

Ardelyx Reports Third Quarter 2021 Financial Results

November 11, 2021

Ardelyx to Present at the Jefferies London Healthcare Conference

November 10, 2021

Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN's Kidney Week 2021

November 4, 2021

Ardelyx to Pursue Formal Dispute Resolution for Tenapanor

November 3, 2021

Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021

October 28, 2021

Ardelyx Provides Corporate Update Following Type A Meeting with FDA

October 12, 2021

Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial

September 2, 2021

Ardelyx Reports Second Quarter 2021 Financial Results

August 12, 2021

Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

July 28, 2021

Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

July 18, 2021

Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021

June 6, 2021

Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference

May 24, 2021

Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights

May 5, 2021

Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

April 28, 2021

Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 15, 2021

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan

April 13, 2021

Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021

April 11, 2021

Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings

March 29, 2021

Ardelyx Appoints Muna Bhanji, R.Ph, to its Board of Directors

March 14, 2021

Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

March 7, 2021

Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference

February 16, 2021

Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

November 22, 2020

Ardelyx to Present at the Jefferies Virtual London Healthcare Conference

November 9, 2020

Ardelyx to Webcast Virtual Analyst Day

November 5, 2020

Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights

November 4, 2020

Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020

October 21, 2020

Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020

October 21, 2020

Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020

October 11, 2020

Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

September 14, 2020

Ardelyx to Participate in Three Upcoming Investor Conferences in September

September 7, 2020

Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights

August 5, 2020

Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor

August 2, 2020

Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

June 29, 2020

Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis

June 14, 2020

Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer

June 7, 2020

Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference

May 25, 2020

Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer

May 17, 2020

Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights

May 6, 2020

Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors

March 15, 2020

Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

March 5, 2020

Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference

February 25, 2020

Ardelyx Announces Pricing of Upsized Public Offering of Common Stock

December 3, 2019

Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis

December 2, 2019

Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study

December 1, 2019

Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements

November 24, 2019

Ardelyx Announces Presentation at Kidney Week 2019

November 5, 2019

Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment

September 2, 2019

Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights

August 8, 2019

← Newer news releases

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.